Neumora Therapeutics, Inc. Common Stock
$0.73
-$0.02 (-2.67%)
$0.71Day Range$0.76
Key Statistics
Market Cap
$140.92M
Shares Outstanding
187.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 15, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$0.74
Day High
$0.76
Day Low
$0.71
Volume
3.88M
VWAP
$0.73
Prev Close
$0.75
Transactions
--
Acc. Volume
--
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283663 employees260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472(857) 760-0900IPO Sep 15, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001885522
- Composite FIGI
- BBG012W9C4X1
- Share Class FIGI
- BBG012W9C504
- Ticker Root
- NMRA
- SIC Code
- 2836
About Neumora Therapeutics, Inc. Common Stock (NMRA) Stock
Neumora Therapeutics, Inc. Common Stock (NMRA) closed the 2026-09-18 session at $0.73, down 2.67% versus the previous close (-0.02). The stock opened at $0.74 and traded between $0.71 and $0.76 during that session. Session trading volume was 3.9M shares. The volume-weighted average price (VWAP) is $0.73.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Neumora Therapeutics, Inc. Common Stock has a market capitalization of $140.9 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. NMRA is listed on the XNAS exchange. The company employs approximately 63 people. Neumora Therapeutics, Inc. Common Stock is headquartered in WATERTOWN, MA. The recorded listing date is 2023-09-15.
On this page you can find market NMRA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.